Drug Database
US

ustekinumab (Absimky / DMB 3115 / DA3115)

✓ Approved

Meiji Seika Pharma Co., Ltd. · IL12B · 单克隆抗体

什么是 ustekinumab?

ustekinumab 是一种单克隆抗体,由Meiji Seika Pharma Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Absimky, DMB 3115, DA3115
公司Meiji Seika Pharma Co., Ltd.
药物类别单克隆抗体, 抗体
分子靶点IL12B, IL23A
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

ustekinumab 作用于 2 个分子靶点:

IL12Binterleukin 12B (CLMF2, CLMF)
IL23Ainterleukin 23 subunit alpha (P19, SGRF)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

ustekinumab 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Musculoskeletal and connective tissue disordersPsoriatic arthropathy✓ Approved

相关研究文献

PubMedTherapeutic advances in gastroenterology2026-11-18

Real-world comparative effectiveness and persistence of ustekinumab versus vedolizumab across cohort mean age in Crohn's disease: A systematic review and meta-analysis with meta-regression.

Lee Jong Yoon JY, Kim Hyun Jung HJ, Lee Jung Won JW, Kim Jae Hyun JH et al.

Selecting biologic therapy for older patients with inflammatory bowel disease is challenging given limited age-specific data. We examined whether cohort mean age is associated with the comparative effectiveness and persistence of ustekinumab (UST) versus vedolizumab (VDZ). Systematic review and meta-analysis with meta-regression of real-world comparative studies. We searched MEDLINE, Embase, Cochrane CENTRAL, and KoreaMed from inception to January 9, 2026 for real-world comparative studies reporting adjusted estimates, and synthesized 48-52 week effectiveness and persistence separately using inverse-variance random-effects models, exploring age effects by subgroup analysis and meta-regression. Seventeen publications comprising 18 cohorts were included, with Crohn's disease (CD) predominating and ulcerative colitis data limited. Pooled effectiveness favored UST in CD (adjusted odds ratio 1.70, 95% confidence interval 1.13-2.56) but not in the stratum with a cohort mean age of ≥60 years (0.91, 0.32-2.56), with a significant between-subgroup difference (P = 0.0038). Cohort mean age was not a significant moderator of effectiveness in meta-regression (slope -0.0393, P = 0.093; eβ 0.96 per year, 95% CI 0.92-1.01). Persistence favored UST (adjusted hazard ratio 1.59, 1.21-2.10) with no age association (P = 0.903), and biologic-naive proportion was not a significant moderator. In CD, UST was favored over VDZ for both effectiveness and persistence, and its effectiveness advantage appeared to attenuate with increasing cohort mean age. Because these are study-level data, this age-related pattern warrants confirmation through patient-level analyses and dedicated studies in older adults, in whom direct comparative evidence remains limited.

PMID 43047869
阅读全文 →
PubMedCurrent medical research and opinion2026-11-16

Surgery rates in Japan around market-entry milestones of advanced therapies for Crohn's disease and ulcerative colitis: an interrupted time-series study using a large-scale Japanese claims database.

Mori Mitsuhiro M, Nakao Yoko M YM, Kozu Takumi T, Kawakami Koji K

Whether the market entry of newer advanced therapies is associated with changes in surgery rates for inflammatory bowel disease in routine clinical practice remains unclear. We aimed to describe surgery rates for Crohn's disease and ulcerative colitis in Japan around the market-entry milestones of advanced therapies. This interrupted time-series study used a large-scale, outpatient-inclusive health insurance claims database from Japan (2012-2020). Prespecified intervention points were the market-entry months of ustekinumab for Crohn's disease (May 2017) and vedolizumab for ulcerative colitis (November 2018). The primary outcome was monthly surgery rates, modeled using segmented Poisson regression with an offset for patients at risk. The cohorts included 5,411 patients with Crohn's disease and 37,052 with ulcerative colitis. Surgery rates declined during the pre-intervention period (incidence rate ratios [95% confidence intervals]: Crohn's disease, 0.993 [0.988-0.999]; ulcerative colitis, 0.994 [0.988-1.001]). No evidence of a level or post-intervention trend change was observed at the intervention points (Crohn's disease: level change, 0.924 [0.708-1.202]; trend change, 1.000 [0.984-1.015]; ulcerative colitis: level change, 0.883 [0.588-1.309]; trend change, 1.008 [0.984-1.032]). Surgery rates showed a gradual pre-existing decline with no detectable level or trend change around these market-entry milestones. These findings suggest that changes in surgical rates may occur gradually rather than as an abrupt shift around a single market-entry milestone.

PMID 43037158
阅读全文 →
PubMedScandinavian journal of gastroenterology2026-11-16

Endoscopic remission in Crohn's disease differs by location and is differentially influenced by disease duration.

Wong Emily C L ECL, Marshall John K JK, Ma Christopher C, Jairath Vipul V et al.

Endoscopic remission (ER) is a key therapeutic goal in Crohn's disease (CD), yet mucosal healing is less frequent in the ileum than in the colon. While longer disease duration reduces the likelihood of ER, whether this effect differs by location is unclear. We conducted a post hoc pooled analysis of individual patient data from four trials (EXTEND, VISIBLE-2, VERSIFY and SEAVUE) via Vivli protocol #10706. A total of 422 patients with baseline Simple Endoscopic Score for Crohn's Disease (SES-CD) >3 treated with adalimumab, vedolizumab or ustekinumab and with week-52 endoscopic data were included. Patients were categorized as ileal (n = 332) or colonic (n = 303). ER was defined as SES-CD = 0 or <3. Associations between disease duration (<1, <2, <3 years vs. longer) and ER were analyzed using chi-square tests and logistic regression adjusted for treatment. Shorter disease duration was associated with higher ER rates overall (SES-CD <3: 35.9% vs. 24.1%, p = 0.018; adjusted OR [aOR] 0.57, 95% CI: 0.32-0.99, p = 0.049). In ileal disease, shorter duration modestly increased ER (31.8% vs. 21.3%, p = 0.048) but was not significant after adjustment (aOR 0.68, 95% CI: 0.39-1.19, p = 0.18). In colonic disease, the association was stronger (SES-CD <3: 39.5% vs. 18.9%, p < 0.001; aOR 0.44, 95% CI: 0.24-0.78, p = 0.005). Shorter disease duration predicts higher ER rates, particularly in colonic CD. These findings suggest earlier initiation of biologic therapy may improve healing in colonic disease, whereas ileal healing may be limited by location-specific factors.

PMID 43037208
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Uveitis in Patients with Inflammatory Bowel Disease: Pharmacovigilance Signal Detection and Nationwide Claims-Based Evaluation.

Hwang Sunjin S, Kim Jiyeong J, Hong Eun Hee EH, Chung Jee-Eun JE et al.

Background/Objectives: To evaluate uveitis risk among biologic users with IBD using signal detection and nationwide outcome data. Methods: We performed a disproportionality analysis of the FDA Adverse Event Reporting System and a retrospective nationwide cohort study of 7862 Korean patients with IBD who initiated adalimumab, vedolizumab, or ustekinumab between 2015 and 2024. Incident uveitis, identified by diagnostic codes, was compared before and after biologic initiation in exploratory analyses to calculate incidence rate ratios, with post-exposure divided into 0-90 and beyond 90 days; cumulative incidence and multivariable Cox regression were also assessed. Post-switch uveitis risk was compared between patients switching from adalimumab to vedolizumab or ustekinumab. Results: Disproportionality analysis identified positive signals for adalimumab (reporting odds ratio, 4.97) and vedolizumab (2.80), but not ustekinumab (0.63). No statistically significant increase in uveitis incidence was observed after biologic initiation in the cohort. No events occurred within 90 days of vedolizumab or ustekinumab initiation; beyond 90 days, incidence rate ratios were 1.3 (95% confidence interval [CI], 0.6-2.9) and 0.6 (95% CI, 0.2-1.7). Adjusted cumulative incidence at the end of follow-up was 1.1%, 0.6%, and 0.2% for adalimumab, vedolizumab, and ustekinumab, with no significant differences on Cox regression. Post-switch risk was similar between vedolizumab and ustekinumab (hazard ratio, 0.88; 95% CI, 0.14-5.58). Conclusions: Pharmacovigilance signals for adalimumab and vedolizumab were not reproduced in a nationwide cohort, in which no statistically significant difference in uveitis risk was detected among the three biologics. Given the small number of events and potential selection bias, these descriptive findings do not exclude clinically important differences between treatments.

PMID 43030435
阅读全文 →
PubMedZeitschrift fur Gastroenterologie2026-11-14

[Adjunctive enteral nutrition in Crohn's disease during biologic therapy: More than a supportive measure? A narrative review].

Peters Sarah S, Tessmer Lea L, Dignass Axel A, Stein Jürgen J

This narrative review aimed to critically evaluate evidence for combining enteral nutrition (EN) with biologic therapy in adults with Crohn's disease (CD). PubMed, Embase and the Cochrane Library were searched on EN combined with biologics, incl. infliximab, adalimumab, vedolizumab, and ustekinumab. Studies published from 01/2018-06/2026 and current clinical guidelines were considered. The evidence was evaluated regarding clinical effectiveness and methodological limitations. Current evidence suggests that adding enteral nutrition to biologic therapy may relatively increase clinical and endoscopic remission rates by up to 50 % compared with biologic monotherapy. The potential benefit may be due to enhanced mucosal healing, alterations in the intestinal microbiome, and improved pharmacokinetics. Higher rates of transmural healing and lower relapse, treatment escalation, and surgery rates have also been reported. While exclusive EN has a broader evidence base, partial EN may offer advantages in clinical practice because of its greater feasibility and acceptability. Evidence is limited by selection bias, heterogeneous treatment protocols and lack of blinding. Combining EN with biologics is a promising therapeutic approach for adults with CD. Prospective RCTs are needed to establish efficacy, safety and optimal use of exclusive and partial EN.

PMID 43025458
阅读全文 →
PubMedInflammatory bowel diseases2026-11-13

Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study.

Nuzzo Alexandre A, Harb Marc M, Stefanescu Carmen C, Berea Teodor T et al.

In corticosteroid-resistant acute severe ulcerative colitis (ASUC), cyclosporine is frequently used in biologic-exposed patients, but data on maintenance strategies after cyclosporine response remain limited. We aimed to describe 12-month outcomes after a cyclosporine-to-biologic bridge and to explore outcomes according to maintenance therapy. This single-center retrospective study screened all patients treated with cyclosporine for ASUC between 2014 and 2024. Patients who responded to cyclosporine and subsequently received vedolizumab or ustekinumab as maintenance therapy were included. The primary endpoint was 12-month colectomy-free survival. Secondary endpoints included steroid-free clinical remission, combined clinical/biological remission, treatment persistence, and adverse events. Comparisons between maintenance therapies were exploratory. Among 67 patients treated with cyclosporine for ASUC, 44 responders were included (35 vedolizumab, 9 ustekinumab, and 96% biologic-exposed). Median follow-up was 39 months. Maintenance therapy was initiated a median of 7 days after cyclosporine initiation. Overall 12-month colectomy-free survival was 73% (95% CI, 61-88). In exploratory analyses, colectomy-free survival appeared lower with ustekinumab than with vedolizumab (47% vs 79%, log-rank P = .03). At 12 months, overall treatment persistence was 46% and combined clinical/biological remission was 34%. Adverse events were predominantly renal or neurological. In this predominantly biologic-exposed, cyclosporine-responsive ASUC cohort, a bridge to vedolizumab or ustekinumab was associated with 73% colectomy-free survival at 12 months and an acceptable safety profile. Comparisons between maintenance therapies remain exploratory.

PMID 43024783
阅读全文 →

注册免费账户还可查看另外 4126 篇文献

免费注册查看全部文献 →

了解更多ustekinumab